Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry

on behalf of the CONNECT MM Registry Investigators

Research output: Contribution to journalArticle

Abstract

Median overall survival (OS) has improved for patients with newly diagnosed multiple myeloma (NDMM), but prognosis varies depending on baseline patient characteristics. Current models use data from selected clinical trial populations, which prevent application to patients in an unselected community setting that reflects routine clinical practice. Using data from the Connect® MM Registry, a large, US, multicentre, prospective observational cohort study (Cohort 1: 2009–2011; Cohort 2: 2012–2016) of 3011 patients with NDMM, we identified prognostic variables for OS via the multivariable analysis of baseline patient characteristics in Cohort 1 (n = 1493) and developed a tool to examine individual outcomes. Factors associated with OS (n = 1450 treated patients; P < 0·05) were age, del(17p), triplet therapy use, EQ-5D mobility, International Staging System stage, solitary plasmacytoma, history of diabetes, platelet count, Eastern Cooperative Oncology Group performance status and serum creatinine, which were used to create survival matrices for 3- and 5-year OS. The model was internally and externally validated using Connect MM Cohort 2 (Harrell's concordance index, 0·698), MM-015 (0·649), and the phase 3 FIRST (0·647) clinical trials. This novel prognostic tool may help inform outcomes for NDMM in the era of triplet therapy use with novel agents.

Original languageEnglish (US)
JournalBritish journal of haematology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Multiple Myeloma
Registries
Survival
Clinical Trials
Plasmacytoma
Hematology
Nuclear Family
Platelet Count
Observational Studies
Creatinine
Cohort Studies
Therapeutics
Serum
Population

Keywords

  • matrix
  • myeloma
  • prognosis
  • registry
  • survival

ASJC Scopus subject areas

  • Hematology

Cite this

Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. / on behalf of the CONNECT MM Registry Investigators.

In: British journal of haematology, 01.01.2019.

Research output: Contribution to journalArticle

@article{5ed52b0232f8425abb3e829383a34f99,
title = "Development of a prognostic model for overall survival in multiple myeloma using the Connect{\circledR} MM Patient Registry",
abstract = "Median overall survival (OS) has improved for patients with newly diagnosed multiple myeloma (NDMM), but prognosis varies depending on baseline patient characteristics. Current models use data from selected clinical trial populations, which prevent application to patients in an unselected community setting that reflects routine clinical practice. Using data from the Connect{\circledR} MM Registry, a large, US, multicentre, prospective observational cohort study (Cohort 1: 2009–2011; Cohort 2: 2012–2016) of 3011 patients with NDMM, we identified prognostic variables for OS via the multivariable analysis of baseline patient characteristics in Cohort 1 (n = 1493) and developed a tool to examine individual outcomes. Factors associated with OS (n = 1450 treated patients; P < 0·05) were age, del(17p), triplet therapy use, EQ-5D mobility, International Staging System stage, solitary plasmacytoma, history of diabetes, platelet count, Eastern Cooperative Oncology Group performance status and serum creatinine, which were used to create survival matrices for 3- and 5-year OS. The model was internally and externally validated using Connect MM Cohort 2 (Harrell's concordance index, 0·698), MM-015 (0·649), and the phase 3 FIRST (0·647) clinical trials. This novel prognostic tool may help inform outcomes for NDMM in the era of triplet therapy use with novel agents.",
keywords = "matrix, myeloma, prognosis, registry, survival",
author = "{on behalf of the CONNECT MM Registry Investigators} and Terebelo, {Howard R.} and Rafat Abonour and Gasparetto, {Cristina J.} and Kathleen Toomey and Durie, {Brian G.M.} and Hardin, {James W.} and Sundar Jagannath and Lynne Wagner and Mohit Narang and Flick, {E. Dawn} and Shankar Srinivasan and Lihua Yue and Amani Kitali and Amit Agarwal and Rifkin, {Robert M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bjh.16139",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry

AU - on behalf of the CONNECT MM Registry Investigators

AU - Terebelo, Howard R.

AU - Abonour, Rafat

AU - Gasparetto, Cristina J.

AU - Toomey, Kathleen

AU - Durie, Brian G.M.

AU - Hardin, James W.

AU - Jagannath, Sundar

AU - Wagner, Lynne

AU - Narang, Mohit

AU - Flick, E. Dawn

AU - Srinivasan, Shankar

AU - Yue, Lihua

AU - Kitali, Amani

AU - Agarwal, Amit

AU - Rifkin, Robert M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Median overall survival (OS) has improved for patients with newly diagnosed multiple myeloma (NDMM), but prognosis varies depending on baseline patient characteristics. Current models use data from selected clinical trial populations, which prevent application to patients in an unselected community setting that reflects routine clinical practice. Using data from the Connect® MM Registry, a large, US, multicentre, prospective observational cohort study (Cohort 1: 2009–2011; Cohort 2: 2012–2016) of 3011 patients with NDMM, we identified prognostic variables for OS via the multivariable analysis of baseline patient characteristics in Cohort 1 (n = 1493) and developed a tool to examine individual outcomes. Factors associated with OS (n = 1450 treated patients; P < 0·05) were age, del(17p), triplet therapy use, EQ-5D mobility, International Staging System stage, solitary plasmacytoma, history of diabetes, platelet count, Eastern Cooperative Oncology Group performance status and serum creatinine, which were used to create survival matrices for 3- and 5-year OS. The model was internally and externally validated using Connect MM Cohort 2 (Harrell's concordance index, 0·698), MM-015 (0·649), and the phase 3 FIRST (0·647) clinical trials. This novel prognostic tool may help inform outcomes for NDMM in the era of triplet therapy use with novel agents.

AB - Median overall survival (OS) has improved for patients with newly diagnosed multiple myeloma (NDMM), but prognosis varies depending on baseline patient characteristics. Current models use data from selected clinical trial populations, which prevent application to patients in an unselected community setting that reflects routine clinical practice. Using data from the Connect® MM Registry, a large, US, multicentre, prospective observational cohort study (Cohort 1: 2009–2011; Cohort 2: 2012–2016) of 3011 patients with NDMM, we identified prognostic variables for OS via the multivariable analysis of baseline patient characteristics in Cohort 1 (n = 1493) and developed a tool to examine individual outcomes. Factors associated with OS (n = 1450 treated patients; P < 0·05) were age, del(17p), triplet therapy use, EQ-5D mobility, International Staging System stage, solitary plasmacytoma, history of diabetes, platelet count, Eastern Cooperative Oncology Group performance status and serum creatinine, which were used to create survival matrices for 3- and 5-year OS. The model was internally and externally validated using Connect MM Cohort 2 (Harrell's concordance index, 0·698), MM-015 (0·649), and the phase 3 FIRST (0·647) clinical trials. This novel prognostic tool may help inform outcomes for NDMM in the era of triplet therapy use with novel agents.

KW - matrix

KW - myeloma

KW - prognosis

KW - registry

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85070696334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070696334&partnerID=8YFLogxK

U2 - 10.1111/bjh.16139

DO - 10.1111/bjh.16139

M3 - Article

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -